Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy

Figure 2 Treatment outcomes of third-line chemotherapy. A: Waterfall plot illustrating the best tumor response during third-line chemotherapy. The evaluation was based on the response evaluation criteria in solid tumors system, with a disease control rate of 26.2%; B: Kaplan-Meier curve showing a median overall survival of 15.3 weeks during third-line chemotherapy; C: Kaplan-Meier curve showing a median progression-free survival of 7.3 weeks during third-line chemotherapy. OS: Overall survival; CI: Confidence interval; PFS: Progression-free survival.